These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Simultaneous activation of muscarinic and GABA Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715 [TBL] [Abstract][Full Text] [Related]
24. Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B J Med Chem; 2013 Oct; 56(20):8196-200. PubMed ID: 24074052 [TBL] [Abstract][Full Text] [Related]
25. Antinociceptive effects of potent, selective and brain penetrant muscarinic M Grauer SM; Sanoja R; Poulin D; Rashid H; Jochnowitz N; Calhoun M; Zwilling D; Varty GB; Rosahl TW; Meziane H; Mittlelhaeuser C; Mazzola R; Morrow J; Smith SM; Henze D; Marcus J Brain Res; 2020 Jun; 1737():146814. PubMed ID: 32234514 [TBL] [Abstract][Full Text] [Related]
26. Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey. Lange HS; Vardigan JD; Cannon CE; Puri V; Henze DA; Uslaner JM Neuropharmacology; 2021 Oct; 197():108754. PubMed ID: 34389398 [TBL] [Abstract][Full Text] [Related]
27. Challenges in the development of an M Wood MR; Noetzel MJ; Poslusney MS; Melancon BJ; Tarr JC; Lamsal A; Chang S; Luscombe VB; Weiner RL; Cho HP; Bubser M; Jones CK; Niswender CM; Wood MW; Engers DW; Brandon NJ; Duggan ME; Conn PJ; Bridges TM; Lindsley CW Bioorg Med Chem Lett; 2017 Jan; 27(2):171-175. PubMed ID: 27939174 [TBL] [Abstract][Full Text] [Related]
29. Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis. Layton ME; Reif AJ; Hartingh TJ; Rodzinak K; Dudkin V; Wang C; Arrington K; Kelly MJ; Garbaccio RM; O'Brien JA; Magliaro BC; Uslaner JM; Huszar SL; Fillgrove KL; Tang C; Kuo Y; Jacobson MA Bioorg Med Chem Lett; 2016 Feb; 26(4):1260-4. PubMed ID: 26810316 [TBL] [Abstract][Full Text] [Related]
30. Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists. Cai C; Kang FA; Hou C; O'Neill JC; Opas E; McKenney S; Johnson D; Sui Z Bioorg Med Chem Lett; 2013 Jan; 23(1):351-4. PubMed ID: 23182090 [TBL] [Abstract][Full Text] [Related]
31. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Nawaratne V; Leach K; Suratman N; Loiacono RE; Felder CC; Armbruster BN; Roth BL; Sexton PM; Christopoulos A Mol Pharmacol; 2008 Oct; 74(4):1119-31. PubMed ID: 18628403 [TBL] [Abstract][Full Text] [Related]
32. Discovery and Development of Muscarinic Acetylcholine M Takai K; Enomoto T Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510 [TBL] [Abstract][Full Text] [Related]
33. Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu Bollinger SR; Engers DW; Panarese JD; West M; Engers JL; Loch MT; Rodriguez AL; Blobaum AL; Jones CK; Thompson Gray A; Conn PJ; Lindsley CW; Niswender CM; Hopkins CR J Med Chem; 2019 Jan; 62(1):342-358. PubMed ID: 30247901 [TBL] [Abstract][Full Text] [Related]
34. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. Nawaratne V; Leach K; Felder CC; Sexton PM; Christopoulos A J Biol Chem; 2010 Jun; 285(25):19012-21. PubMed ID: 20406819 [TBL] [Abstract][Full Text] [Related]
35. Serotonergic-Muscarinic Interaction within the Prefrontal Cortex as a Novel Target to Reverse Schizophrenia-Related Cognitive Symptoms. Cieślik P; Radulska A; Burnat G; Kalinowski L; Wierońska JM Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445318 [TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843 [TBL] [Abstract][Full Text] [Related]
37. Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Felts AS; Rodriguez AL; Morrison RD; Bollinger KA; Venable DF; Blobaum AL; Byers FW; Thompson Gray A; Daniels JS; Niswender CM; Jones CK; Conn PJ; Lindsley CW; Emmitte KA Bioorg Med Chem Lett; 2017 Nov; 27(21):4858-4866. PubMed ID: 28958625 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and pharmacological evaluation of M4 muscarinic receptor positive allosteric modulators derived from VU10004. Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B ACS Chem Neurosci; 2015 Jun; 6(6):838-44. PubMed ID: 25857219 [TBL] [Abstract][Full Text] [Related]